Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).

Detaljer

Författare
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
Originalspråkengelska
Artikelnummer8
TidskriftBMC Clinical Pathology
Volym15
StatusPublished - 2015
PublikationskategoriForskning
Peer review utfördJa

Nedladdningar

Ingen tillgänglig data